S-3ASR filed Jun 26, 2026 at 16:05 ET
{ "summary": "Spyre Therapeutics filed an automatic shelf registration statement (S-3ASR) on June 26, 2026, registering an unlimited amount of securities, and concurrently entered into a $500M at-the-market (ATM) sales agreement with TD Cowen for common stock. The company has a $7.8B market cap, a strong cash position from prior raises, and no disclosed need for immediate capital, making this an opportunistic shelf filing to maintain financial flexibility rather than a distress-driven raise.",